|
Crawford, Howard C; Dempsey, Peter J; Brown, Gordon et al. (2009) ADAM10 as a therapeutic target for cancer and inflammation. Curr Pharm Des 15:2288-99
|
|
Merchant, Nipun B; Voskresensky, Igor; Rogers, Christopher M et al. (2008) TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer. Clin Cancer Res 14:1182-91
|
|
Moss, Marcia L; Stoeck, Alexander; Yan, Wenbo et al. (2008) ADAM10 as a target for anti-cancer therapy. Curr Pharm Biotechnol 9:2-8
|
|
Gelling, Richard W; Yan, Wenbo; Al-Noori, Salwa et al. (2008) Deficiency of TNFalpha converting enzyme (TACE/ADAM17) causes a lean, hypermetabolic phenotype in mice. Endocrinology 149:6053-64
|
|
Sanderson, Michael P; Keller, Sascha; Alonso, Angel et al. (2008) Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metalloprotease-dependent ectodomain shedding and exosome secretion. J Cell Biochem 103:1783-97
|
|
Moss, Marcia L; Bomar, Martha; Liu, Qian et al. (2007) The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events. J Biol Chem 282:35712-21
|
|
Li, Nianyu; Wang, Yao; Forbes, Karen et al. (2007) Metalloproteases regulate T-cell proliferation and effector function via LAG-3. EMBO J 26:494-504
|
|
Li, Nianyu; Boyd, Kelli; Dempsey, Peter J et al. (2007) Non-cell autonomous expression of TNF-alpha-converting enzyme ADAM17 is required for normal lymphocyte development. J Immunol 178:4214-21
|
|
Ohtsu, Haruhiko; Dempsey, Peter J; Frank, Gerald D et al. (2006) ADAM17 mediates epidermal growth factor receptor transactivation and vascular smooth muscle cell hypertrophy induced by angiotensin II. Arterioscler Thromb Vasc Biol 26:e133-7
|
|
Ohtsu, Haruhiko; Dempsey, Peter J; Eguchi, Satoru (2006) ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Am J Physiol Cell Physiol 291:C1-10
|
Showing the most recent 10 out of 16 publications
